6330569M22Rik Inhibitors
Chemical inhibitors of 6330569M22Rik can modulate the protein's function through various biochemical pathways. Wortmannin and LY294002, both targeting the PI3K enzyme, are capable of downregulating the PI3K/AKT/mTOR signaling axis. This inhibition is crucial as it can lead to reduced phosphorylation of AKT and subsequently less activity of mTOR, a central regulator of cell growth and proliferation. Similarly, Rapamycin directly inhibits the mTOR complex 1, which can suppress the mTOR pathway's role in protein synthesis and cell cycle progression. These inhibitors work by interfering with the signaling that may be essential for the activity of 6330569M22Rik.
Further, MEK inhibitors like PD98059 and U0126 can impede the MAPK/ERK pathway by preventing the activation of ERK, a kinase that contributes to cell proliferation and differentiation. SB203580 takes a different route by selectively inhibiting p38 MAP kinase, which is involved in responses to stress signals and cytokines. This inhibition might attenuate the cellular responses associated with 6330569M22Rik. SP600125, as a JNK inhibitor, can influence apoptosis and cell survival by disrupting the JNK signaling pathway. In the realm of tyrosine kinase inhibition, PP2 and Dasatinib act on Src family kinases and BCR-ABL kinases, respectively. PP2's selectivity for Src kinases means it can disrupt numerous signaling pathways, while Dasatinib's broader range of targets allows it to interfere with multiple signaling routes that 6330569M22Rik may utilize. Leflunomide's inhibition of dihydroorotate dehydrogenase can lead to reduced nucleotide synthesis, which is vital for cell proliferation, while Imatinib blocks BCR-ABL, c-Kit, and PDGF receptors, affecting key signaling pathways of proliferation and survival that may involve 6330569M22Rik. Lastly, Sorafenib targets multiple kinases involved in cell proliferation and angiogenesis, which can influence the pathways that include 6330569M22Rik. Each chemical inhibitor, by targeting specific enzymes or kinases, can alter the signaling pathways that are potentially key to the function of 6330569M22Rik.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K, which is a key enzyme in the PI3K/AKT/mTOR pathway, a pathway known to be involved in cell growth, proliferation, and survival. Inhibition of PI3K by Wortmannin can lead to reduced AKT phosphorylation and mTOR activity, thereby inhibiting 6330569M22Rik if it is part of this signaling axis. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a synthetic molecule that selectively inhibits PI3K. Similar to Wortmannin, LY294002's inhibition of PI3K can lead to dampened downstream signaling through the AKT/mTOR pathway, potentially leading to the inhibition of 6330569M22Rik if it is involved in this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that binds to the mTOR complex 1 (mTORC1) and inhibits its activity. By inhibiting mTORC1, Rapamycin can downregulate protein synthesis and cell cycle progression, which can contribute to the functional inhibition of 6330569M22Rik if it plays a role in these mTOR-regulated processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a synthetic compound that inhibits MEK, which phosphorylates and activates ERK in the MAPK/ERK pathway. Inhibition of this pathway can result in reduced cell proliferation and differentiation, potentially leading to the inhibition of 6330569M22Rik if it is associated with this signaling pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a pyridinyl imidazole derivative that selectively inhibits p38 MAP kinase, which is involved in the response to stress signals and cytokines. Inhibition of p38 MAP kinase can attenuate the cellular stress response, potentially leading to the inhibition of 6330569M22Rik if it is linked to this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an anthrapyrazolone inhibitor of c-Jun N-terminal kinase (JNK), which modulates apoptosis, cell survival, and proliferation. By inhibiting JNK, SP600125 can interfere with these cellular processes, potentially leading to the inhibition of 6330569M22Rik if it is part of the JNK signaling pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream regulators of the ERK pathway. By inhibiting MEK1/2, U0126 can prevent the activation of ERK, which is involved in cell cycle regulation and differentiation, possibly leading to the inhibition of 6330569M22Rik if it is involved in the ERK pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. Src kinases are involved in various cell signaling pathways that regulate proliferation and survival. Inhibition of Src kinases by PP2 can disrupt these pathways, potentially leading to the inhibition of 6330569M22Rik if it is implicated in Src signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor with activity against BCR-ABL and Src family kinases. By inhibiting these kinases, Dasatinib can interfere with multiple signaling pathways, potentially leading to the inhibition of 6330569M22Rik if it operates within these pathways. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $83.00 | 5 | |
Leflunomide is a reversible inhibitor of dihydroorotate dehydrogenase, which is involved in de novo pyrimidine synthesis. By inhibiting this enzyme, Leflunomide can result in diminished nucleotide synthesis and reduced proliferation, which can inhibit 6330569M22Rik if it is involved in nucleotide biosynthesis-dependent processes. | ||||||